Objective: To investigate the pathological characteristics of bone marrow in multiple myeloma patients with secondary myelofibrosis and their relationship with prognosis.
Methods: Clinical data of 70 cases of multiple myeloma including 35 patients with secondary myelofibrosis were analyzed retrospectively from January 1st to December 31st 2012 in Department of Hematology of our hospital, the degree of hyperplasia, as well as the changes of myelofibros after treatment were compared between bone marrow smear and biopsy, and their relationship with the prognosis was analysed.
Results: The myelofibrosis could be observed in any stage and type of multiple myeloma, the myelobibrosis could cause the decrease of pseudoepitheliomatous hyperplasia in bone marrow smear, and the increase of reticulin could be observed in the biopsy with Gomori staining + to +++, and the secondary myelofibrosis could be alleviated after treatment. The overall prognosis of these patients was poor.
Conclusion: The bone marrow biopsy has the important diagnostic value for the multiple myeloma patients with secondary myelofibrosis, and the myelofibrosis can be alleviated after treatment, but the overall prognosis of multiple myeloma patients with secondary myelofibrosis is poor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7534/j.issn.1009-2137.2017.04.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chimeric antigen receptor therapy in hematologic malignancies.
JAAPA
January 2025
In the PA program at the University of Florida in Gainesville, Fla., Elizabeth Brownlee is director of didactic education and Melissa Turley is interim program director and a clinical assistant professor. Heather Nations practices in obstetrics and gynecology at UF Health Physicians in Gainesville. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Chimeric antigen receptor (CAR) T-cell therapy has led to significant advances in the treatment of blood cancers such as leukemia, lymphoma, and multiple myeloma, and now shows promise for solid tumors. This type of immunotherapy can achieve high response rates in patients with hematologic malignancies, but carries serious adverse reactions, including cytokine release syndrome and immune-effector cell-associated neurotoxicity syndrome. This article describes CAR T-cell therapy, guidance for primary care providers caring for patients undergoing therapy, and the ongoing need for research to enhance CAR T-cell therapy's safety and effectiveness.
View Article and Find Full Text PDF[Autologous Stem-Cell Transplantation without Transfusion Support in Jehovah's Witness Patients. A case series].
Rev Med Chil
June 2024
Servicio de Medicina física y Rehabilitación, Hospital del Salvador, Santiago, Chile.
Autologous Stem-Cell Transplantation (ASTC) has proven efficacy in several hematological malignancies. The greatest antineoplastic effect achieved with intensified chemotherapy is associated with severe myelotoxicity. The infusion of autologous hematopoietic precursors and transfusion support during the period of aplasia reduces the time and depth of cytopenias, decreasing the risk of bleeding, anemia and life-threatening infections.
View Article and Find Full Text PDFIberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse.
Br J Haematol
January 2025
Service d'hématologie, Centre Hospitalo-Universitaire, Nantes, France.
Most transplant-ineligible patients present with multiple myeloma (MM) refractory to lenalidomide and/or anti-CD38 monoclonal antibody at first relapse and represent a difficult-to-treat population. The Intergroupe Francophone du Myélome phase 2 study iberdomide, ixazomib and dexamethasone (I2D) evaluated the oral triplet iberdomide, ixazomib and dexamethasone in MM patients aged ≥70 years at first relapse (NCT04998786). Seventy patients were enrolled to receive iberdomide (1.
View Article and Find Full Text PDFBoanmycin overcomes bortezomib resistance by inducing DNA damage and endoplasmic reticulum functional impairment in multiple myeloma.
Biol Direct
January 2025
Department of Hematology, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Shenzhen, 518172, China.
Background: Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled proliferation of plasma cells and is currently incurable. Despite advancements in therapeutic strategies, resistance to proteasome inhibitors, particularly bortezomib (BTZ), poses a substantial challenge to disease management. This study aimed to explore the efficacy of boanmycin, a novel antitumor antibiotic, in overcoming resistance to BTZ in MM.
View Article and Find Full Text PDFPatient reported outcomes with earlier use of chimeric antigen receptor-T cell therapy in multiple myeloma.
Lancet Haematol
January 2025
Department of Oncology, McMaster University, Hamilton, ON, Canada. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!